Stay updated with breaking news from King Io. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK - 4 January 2022
New research from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King’s College London, in partnership with COMPASS Pathways, has
London, UK - 3 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental
London, UK 3 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be conducting a phase II clinical trial to assess the safety and tolerability of COMP360 psilocybin therapy in post-traumatic stress disorder . The study expands COMPASS’s research pipeline in psilocybin therapy with COMP360, ...
A new review of current literature, conducted by the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King College London, has found that irreg